Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. articles
  4. article
Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 01 September 2002

Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death

  • Young Do Yoo1,
  • Young Min Chung,
  • Jong Kuk Park,
  • Chul Min Ahn,
  • Sung Kyu Kim &
  • …
  • Hyung Jung Kim 

Experimental & Molecular Medicine volume 34, pages 273–277 (2002)Cite this article

  • 832 Accesses

  • 45 Citations

  • Metrics details

Abstract

Peroxiredoxin II (Prx II) is known not only to protect cells from oxidative damage caused by hydrogen peroxide (H2O2), but also to endow cancer cells with resistance to both H2O2 and cisplatin and to grant them radioresistance. In this study, we examined whether Prx II antisense could enhance cisplatin-induced cell death. When gastric cancer cells were transfected with various concentrations of Prx II antisense plasmid, pPrxII/AS, and then treated with the same concentrations of cisplatin, Prx II antisense enhanced cisplatin-induced cell death. The combination index (CI) at all doses of the combination was below 1, indicating that Prx II antisense sensitized cisplatin-induced cell death. This synergism was also observed in the cells transfected with a Prx II antisense oligomer. Our present results, therefore, suggest that Prx II antisense would be a very good sensitizer for cisplatin, and that Prx II as a target for chemosensitizers constitutes a promising avenue for future research.

Similar content being viewed by others

Platinum iodido drugs show potential anti-tumor activity, affecting cancer cell metabolism and inducing ROS and senescence in gastrointestinal cancer cells

Article Open access 22 March 2024

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Article Open access 06 February 2024

Peroxiredoxin 1 regulates crosstalk between pyroptosis and autophagy in oral squamous cell carcinoma leading to a potential pro-survival

Article Open access 25 November 2023

Article PDF

Author information

Authors and Affiliations

  1. Korea University Cancer Institute, Korea University College of Medicine, Seoul, Korea

    Young Do Yoo

Authors
  1. Young Do Yoo
    View author publications

    Search author on:PubMed Google Scholar

  2. Young Min Chung
    View author publications

    Search author on:PubMed Google Scholar

  3. Jong Kuk Park
    View author publications

    Search author on:PubMed Google Scholar

  4. Chul Min Ahn
    View author publications

    Search author on:PubMed Google Scholar

  5. Sung Kyu Kim
    View author publications

    Search author on:PubMed Google Scholar

  6. Hyung Jung Kim
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Yoo, Y., Chung, Y., Park, J. et al. Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death. Exp Mol Med 34, 273–277 (2002). https://doi.org/10.1038/emm.2002.38

Download citation

  • Published: 01 September 2002

  • Issue date: 01 September 2002

  • DOI: https://doi.org/10.1038/emm.2002.38

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • Prx II
  • cisplatin
  • chemosensitizer
  • antisense
  • multidrug resistance

This article is cited by

  • Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT

    • Haiyan Zhu
    • Xuejiao Tao
    • Xueqiong Zhu

    BMC Cancer (2019)

  • Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells’ survival by protecting cells from oxidative stress

    • Weidong Lu
    • Zhongxue Fu
    • Jinbao Guo

    Molecular and Cellular Biochemistry (2014)

  • Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study

    • Francesca Magherini
    • Alessandra Modesti
    • Luigi Messori

    JBIC Journal of Biological Inorganic Chemistry (2010)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases
  • Open Access Fees and Funding

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med)

ISSN 2092-6413 (online)

ISSN 1226-3613 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited